Koers Bristol-Myers Squibb Company Deutsche Boerse AG
Aandelen
BRM
US1101221083
Farmaceutische producten
Geschatte realtime
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
39,13 EUR | +0,05% | -4,04% | -15,57% |
11:38 | Bristol-Myers Squibb investeert in NeoPhore | MT |
21/05 | Bristol-Myers Squibb zegt dat US FDA actiedatum subcutane Nivolumab opnieuw heeft vastgesteld | MT |
Omzet 2024 * | 46,03 mld. 42,5 mld. | Omzet 2025 * | 46,06 mld. 42,53 mld. | Marktkapitalisatie | 85,69 mld. 79,11 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -5,41 mld. -5 mld. | Nettowinst (verlies) 2025 * | 10,22 mld. 9,44 mld. | EV/omzet 2024 * | 2,72 x |
Nettoschuld 2024 * | 39,31 mld. 36,3 mld. | Nettoschuld 2025 * | 32,04 mld. 29,58 mld. | EV/omzet 2025 * | 2,56 x |
K/w-verhouding 2024 * |
-16,1
x | K/w-verhouding 2025 * |
8
x | Werknemers | 34.100 |
Dividendrendement 2024 * |
5,69% | Dividendrendement 2025 * |
5,98% | Vrij verhandelbaar | 69,27% |
Recentste transcriptie over Bristol-Myers Squibb Company
1 dag | +0,05% | ||
1 week | -4,04% | ||
Lopende maand | -6,17% | ||
1 maand | -15,04% | ||
3 maanden | -16,29% | ||
6 maanden | -12,76% | ||
Lopend jaar | -15,57% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 53 | 01-02-15 | |
David Elkins
DFI | Director of Finance/CFO | 55 | 20-11-19 |
Greg Meyers
CTO | Chief Tech/Sci/R&D Officer | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Phyllis Yale
BRD | Director/Board Member | 66 | 20-11-19 |
Peter Arduini
BRD | Director/Board Member | 59 | 01-04-16 |
Derica Rice
BRD | Director/Board Member | 59 | 01-09-20 |
Datum | Koers | Variatie | Volume |
---|---|---|---|
22-05-24 | 39,34 | +0,60% | 289 |
21-05-24 | 39,11 | -3,10% | 3 401 |
20-05-24 | 40,36 | -0,04% | 660 |
17-05-24 | 40,38 | -0,38% | 1 926 |
16-05-24 | 40,53 | -1,15% | 1 398 |
uitgestelde koers Deutsche Boerse AG, 22 mei 2024 om 10:34 uur
Meer koersenHerzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+37,78% | 723 mld. | |
+31,10% | 598 mld. | |
-3,51% | 364 mld. | |
+19,94% | 331 mld. | |
+5,14% | 288 mld. | |
+16,19% | 244 mld. | |
-4,87% | 208 mld. | |
+10,02% | 210 mld. | |
+9,32% | 169 mld. |